These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7955801)

  • 21. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.
    Meier UT; Dayer P; Malè PJ; Kronbach T; Meyer UA
    Clin Pharmacol Ther; 1985 Nov; 38(5):488-94. PubMed ID: 4053486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
    Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH; Wood AJ
    Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
    Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
    Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphic drug metabolism.
    Relling MV
    Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S-mephenytoin hydroxylation phenotypes in a Jordanian population.
    Hadidi HF; Irshaid YM; Woosley RL; Idle JR; Flockhart DA
    Clin Pharmacol Ther; 1995 Nov; 58(5):542-7. PubMed ID: 7586948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome.
    Silver RM; Sutherland SE; Carreira P; Heyes MP
    J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
    Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
    de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
    Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic aspects of drug disposition and therapeutics.
    Guttendorf RJ; Wedlund PJ
    J Clin Pharmacol; 1992 Feb; 32(2):107-17. PubMed ID: 1613119
    [No Abstract]   [Full Text] [Related]  

  • 36. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
    Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
    J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
    Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P-31 magnetic resonance spectroscopy of skeletal muscle in the eosinophilia-myalgia syndrome: a preliminary study.
    Clauw DJ; Hewes B; Nelson M; Katz P; Rajan S
    J Rheumatol; 1994 Apr; 21(4):654-7. PubMed ID: 8035389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H; Nielsen KK; Brøsen K
    Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
    Daniel HI; Edeki TI
    Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.